Greg Zante sold $1.9M of VKTX
Chief Financial Officer at Viking Therapeutics, Inc.. 57,661 shares at an average of $32.90, traded Jan 5, 2026, filed Jan 5, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.9M at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.0%, 3m +5.6%, 6m +20.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-003116, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | AGrant or award Common Stock, par value $0.00001 per share | +41,000 | $0.00 | $0 | 215,483 | Jan 5, 2026 |
| Jan 2, 2026 | AGrant or award Common Stock, par value $0.00001 per share | +32,049 | $0.00 | $0 | 247,532 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock, par value $0.00001 per share | -31,961 | $32.30 | $1.0M | 215,571 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock, par value $0.00001 per share | -13,900 | $33.38 | $464k | 201,671 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock, par value $0.00001 per share | -10,300 | $34.24 | $353k | 191,371 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock, par value $0.00001 per share | -1,500 | $32.09 | $48k | 189,891 | Jan 5, 2026 |
| Jan 2, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 5, 2026 |
Related signals
Other insiders at Viking Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $4.9M 148,517 shares | -5% | |
| 55Moderate | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $610k 18,217 shares | -4% | |
| 58Moderate | Viking Therapeutics, Inc. | Greg Zante Chief Financial Officer | $710k 21,217 shares | -9% | |
| 38Weak | VKTXbuy Viking Therapeutics, Inc. | Neil William Aubuchon Chief Commercial Officer | $150k 4,475 shares | - | |
| 39Weak | Viking Therapeutics, Inc. | Matthew W Foehr director | $562k 16,000 shares | -11% | |
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $7.7M 233,409 shares | -9% | |
| 65Notable | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $1.9M 57,661 shares | -12% | |
| 65Notable | Viking Therapeutics, Inc. | Brian Lian President & CEO | $1.4M 38,989 shares | -2% | |
| 47Moderate | Viking Therapeutics, Inc. | Marianna Mancini Chief Operating Officer | $216k 6,185 shares | -2% | |
| 60Notable | Viking Therapeutics, Inc. | Charles A Rowland Jr director | $2.1M 60,000 shares | -67% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.